|
Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult …
DigitalJournal.com Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of CIMZIA … |
|
Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult …
MarketWatch Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of CIMZIA … |
John McCamant Scans Under the Radar for Promising BiotechsVantage WireVice president of sales Michael Crum arrived in January after 13 years at Genentech (Roche Holding AG (RHHBY:OTCQX)), cross-trained in selling cancer treatments including Rituxan (ri…
DC Week: ACA Defunding Fight ContinuesMedPage TodayBoxed Warning of HBV Risk Added to Rituxan, Arezerra. The FDA announced Friday that rituximab (Rituxan) and ofatumumab (Arzerra) will now carry a boxed warning stating the risk for immunosuppression-re…
|
Halozyme earns $10 million milestone payment from Roche for launch of …
pharmabiz.com In February 2011, Roche began a phase III registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL) and submitted a line extension … |
The Right Stuff – And The Wrong Stuff: Britain Awards 1.2 Million Pounds to …ProHealthCurrently Invest in ME and our supporters are actually initiating, organising and funding possibly the two most important ME research studies currently in the UK – …
MedscapeImmunotherapy Helps Epileptic Patients With Neural AntibodiesMedscapeShe noted that for longer-term therapy, immunoglobulins and drugs such as rituximab are indicated. Corticosteroids have unacceptable adverse effects, and plasmapheresis is imp…
|
Halozyme Therapeutics, Inc. (HALO): Halozyme’s CEO Presents at BioCentury …
Seeking Alpha If we look across the board whether or not it’d be Roche, product like Herceptin or rituximab, taking these from IV to subcutaneous administration. This is something that we have two products now which have seen European launches in the last quarter … |
John McCamant Scans Under the Radar for Promising BiotechsWall Street Sector SelectorVice president of sales Michael Crum arrived in January after 13 years at Genentech (Roche Holding AG (RHHBY:OTCQX)), cross-trained in selling cancer treatments includ…
Rituximab maintenance did not significantly extend PFS in follicular lymphomaHealioA brief induction with rituximab, fludarabine, mitoxantrone and dexamethasone followed by rituximab consolidation was associated with high complete response and PFS rate…